SETBP1 status at diagnosis affects outcome. (A) EFS in patients with a SETBP1 mutation was significantly lower than those without a mutation in the AAML0122 clinical trial (P = .006). (B) EFS in patients with a subclonal SETBP1 mutation that was only detectable by ddPCR was significantly lower than in those without a mutation (P = .004). (C) OS in patients with a SETBP1 mutation compared with those without a mutation (P = .258). (D) OS in patients with a subclonal mutation compared with those without any mutation (P = .507).